Management of idiopathic membranous nephropathy

Bibliography

• Debiec H, Guigonis V, Mougenot B, Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002;346:2053-60
   PubMed Web of Science ®Google Scholar
• Beck LH Jr, Bonegio RG, Lambeau G, M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21
   PubMed Web of Science ®Google Scholar
• Prunotto M, Carnevali ML, Candiano G, Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010;21:507-19
   PubMedGoogle Scholar
• Ponticelli C. Membranous nephropathy. J Nephrol 2007;20:268-87
   PubMed Web of Science ®Google Scholar
• Cattran DC. Idiopathic membranous nephropathy. Kidney Int 2001;59:1983-94
   PubMed Web of Science ®Google Scholar
• Blainey JD, Brewer DB, Hardwicke J. Proteinuric glomerular disease in adults: cumulative life tables over twenty years. Q J Med 1986;59:557-67
   PubMedGoogle Scholar
• Donadio JV Jr, Torres VE, Velosa JA, Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988;33:708-15
   PubMed Web of Science ®Google Scholar
• Noel LH, Zanetti M, Droz D, Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 1979;66:82-90
   PubMed Web of Science ®Google Scholar
• Troyanov S, Roasio L, Pandes M, Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int 2006;69:1641-8
   PubMed Web of Science ®Google Scholar
• Cattran DC, Pei Y, Greenwood CM, Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997;51:901-7
   PubMed Web of Science ®Google Scholar
• Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol 2005;16(Suppl 1):S58-63
   PubMedGoogle Scholar
• Benigni A, Tomasoni S, Gagliardini E, Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001;12:941-8
   PubMed Web of Science ®Google Scholar
• Praga M, Borstein B, Andres A. Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 1991;17:330-8
   PubMed Web of Science ®Google Scholar
• Ambalavanan S, Fauvel JP, Sibley RK, Myers BD. Mechanism of the antiproteinuric effect of cyclosporine in membranous nephropathy. J Am Soc Nephrol 1996;7:290-8
   PubMed Web of Science ®Google Scholar
• Stegeman CA, De Zeeuw D, de Jong PE. Treatment of idiopathic membranous nephropathy: the dilemma of who, when, and how. Nephrol Dial Transplant 1995;10:1982-4
   PubMedGoogle Scholar
• Bellomo R, Atkins RC. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 1993;6:249-54
   Google Scholar
• Sarasin FP, Schifferli JA. Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 1994;45:578-85
   PubMedGoogle Scholar
• Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum. J Am Soc Nephrol 2007;18:2221-5
   PubMed Web of Science ®Google Scholar
• Hladunewich MA, Troyanov S, Calafati J, The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol 2009;4:1417-22
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Passerini P, Altieri P, Remissions and relapses in idiopathic membranous nephropathy. Nephrol Dial Transplant 1992;7(Suppl 1):85-90
   PubMedGoogle Scholar
• Troyanov S, Wall CA, Miller JA, Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 2004;66:1199-20
   PubMed Web of Science ®Google Scholar
• Polanco N, Gutiérrez E, Covarsí A, Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010;21:697-704
   PubMed Web of Science ®Google Scholar
• Cattran DC, Reich HN, Beanlands HJ, The impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 2008;23:2247-53
   PubMed Web of Science ®Google Scholar
• Ponticelli C. Glucocorticoids and immunomodulating agents in treatment of primary glomerulonephritis. In: Ponticelli C, Glassock RJ, editors, Oxford University Press, Oxford; 2009. p. 47-127
   Google Scholar
• Hopper J Jr, Trew PA, Biava CG. Membranous nephropathy: its relative benignity in women. Nephron 1981;29:18-24
   PubMedGoogle Scholar
• Shiiki H, Saito T, Nishitani Y, Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int 2004;65:1400-7
   PubMed Web of Science ®Google Scholar
• Black DAK, Rose G, Brewer DB. Controlled trial of prednisone in adult patients with nephrotic syndrome. Br Med J 1970;3:421-6
   PubMed Web of Science ®Google Scholar
• Cattran DC, Delmore T, Roscoe J, A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 1989;320:8-13
   PubMedGoogle Scholar
• Cameron JS, Healy MJ, Adu D. The medical research council trial of short-term high-dose alternate-day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. Q J Med 1990;274:133-56
   Google Scholar
• Collaborative study of the adult idiopathic nephrotic syndrome: a controlled study of short-term prednisone treatment in adults with membranous nephropathy. N Engl J Med 1979;301:1301-6
   PubMed Web of Science ®Google Scholar
• Hogan SL, Muller KE, Jennette JC, A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995;25:862-75
   PubMed Web of Science ®Google Scholar
• Lagrue G, Bernard D, Bariety J, Traitement par le chlorambucil et l'azathioprine dans les glomerulonephrites primitives: resultats d'une etude controllée. J Urol Nephrol 1975;81:655-72
   PubMedGoogle Scholar
• Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis. Clin Nephrol 1992;37:229-34
   PubMed Web of Science ®Google Scholar
• Donadio JV Jr, Torres VE, Velosa JA, Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int 1988;33:708-15
   PubMed Web of Science ®Google Scholar
• du Buf-Vereijken PW, Branten AJ, Wetzels JF, Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant 2004;19:1142-8
   PubMed Web of Science ®Google Scholar
• Hofstra JM, Branten AJ, Wirtz JJ, Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial. Nephrol Dial Transplant 2010;25:129-36
   PubMed Web of Science ®Google Scholar
• Faurschou M, Sorensen IJ, Mellemkjaer L, Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 2008;35:100-5
   PubMed Web of Science ®Google Scholar
• Jacob HS. Pulse steroids in haematological diseases. Hosp Pract 1985;8:87-94
   Google Scholar
• Weil JM, Packard BG. Methylprednisolone inhibits the alternative and amplification pathways of complement. Infect Immun 1982;38:122-6
   PubMedGoogle Scholar
• Ponticelli C, Zucchelli P, Imbasciati E, Methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1984;310:946-50
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Zucchelli P, Passerini P, A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600-4
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Zucchelli P, Passerini P, Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. N Engl J Med 1992;327:599-603
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Altieri P, Scolari F, A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998;9:444-50
   PubMed Web of Science ®Google Scholar
• Passerini P, Ponticelli C. Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy. Semin Nephrol 2003;23:355-61
   PubMedGoogle Scholar
• Jha V, Ganguli A, Saha TK, A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007;18:1899-904
   PubMed Web of Science ®Google Scholar
• Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004;19:1305-7
   PubMed Web of Science ®Google Scholar
• Picardi L, Villa G, Galli F, ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clin Nephrol 2004;62:403-4
   PubMedGoogle Scholar
• Ponticelli C, Passerini P, Salvadori M, A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006;47:233-40
   PubMed Web of Science ®Google Scholar
• Arnadottir M, Stefansson B, Berg AL. A randomized study on treatment with adrenocorticotrophic hormone in idiopathic membranous nephropathy. J Am Soc Nephrol 2006;17:571A
   Google Scholar
• Rauen T, Michaelis A, Floege J, Mertens PR. Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24. Clin Nephrol 2009;71:637-42
   PubMedGoogle Scholar
• Ghiggeri GM, Bruschi M, Candiano G, Depletion of clusterin in renal diseases causing nephritic syndrome. Kidney Int 2002;62:2184-94
   PubMedGoogle Scholar
• Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol 2002;2:725-34
   PubMed Web of Science ®Google Scholar
• Faul C, Donnelly M, Merscher-Gomez S, The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-8
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Villa M. Does cyclosporine have a role in treatment of membranous nephropathy? Nephrol Dial Transplant 1999;14:23-5
   PubMedGoogle Scholar
• Alexopoulos E, Pagianni A, Tsamelashvili M, Induction and long-term treatment of membranous nephropathy with nephrotic syndrome. Nephrol Dial Transplant 2006;21:3127-32
   PubMed Web of Science ®Google Scholar
• Ransom RF, Lam NG, Hallett MA, Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 2005;68:2473-83
   PubMed Web of Science ®Google Scholar
• Fritsche L, Budde K, Farber L, Treatment of membranous glomerulopathy with cyclosporin A: how much patience is required? Nephrol Dial Transplant 1999;14:1036-8
   PubMedGoogle Scholar
• Cattran DC, Appel GB, Hebert LA, Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int 2001;59:1484-90
   PubMed Web of Science ®Google Scholar
• Cattran DC, Alexopoulos E, Heering P, Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int 2007;72:1429-4
   PubMed Web of Science ®Google Scholar
• Praga M, Barrio V, Juarez GF, Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int 2007;71:924-30
   PubMed Web of Science ®Google Scholar
• Nangaku M, Pippin J, Richardson CA, Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. Kidney Int 1996;50:2054-62
   PubMedGoogle Scholar
• Yokoyama H, Goshima S, Wada T, The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Nephrol Dial Transplant 1999;14:2379-86
   PubMedGoogle Scholar
• Allison AC, Eugui EM, Sollinger HW. Micophenolate mofetil: mechanism of action and effects in transplantation. Transplant Rev 1993;7:129-39
   Google Scholar
• Branten AJ, du Buf-Vereijken PW, Vervloet M, Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007;50:248-56
   PubMed Web of Science ®Google Scholar
• Dussol B, Morange S, Burtey S, Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial. Am J Kidney Dis 2008;52:699-705
   PubMed Web of Science ®Google Scholar
• Chan TM, Lin AW, Tang SC, Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology (Carlton) 2007;12:576-81
   PubMed Web of Science ®Google Scholar
• Senthil Nayagam L, Ganguli A, Rathi M, Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrol Dial Transplant 2008;23:1926-30
   PubMed Web of Science ®Google Scholar
• Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932-7
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68
   PubMed Web of Science ®Google Scholar
• Waldman M, Appel GB. Update on the treatment of lupus nephritis. Kidney Int 2006;70:1403-12
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Chiurchiu C, Abbate M, Rituximab for idiopathic membranous nephropathy. Lancet 2002;360:923-4
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Chiurchiu C, Abbate M, Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 2006;1:738-48
   PubMed Web of Science ®Google Scholar
• Fervenza FC, Cosio FG, Erickson SB, Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008;73:117-25
   PubMed Web of Science ®Google Scholar
• Segarra A, Praga M, Ramos N, Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009;4:1083-8
   PubMed Web of Science ®Google Scholar
• Bomback AS, Derebail VK, McGregor JG, Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol 2009;4:734-44, 117
   PubMed Web of Science ®Google Scholar
• Appel G, Nachman P, Hogan S, Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 2002;13:A68
   Google Scholar
• Mathieson PW, Turner AN, Maidment CG, Prednisolone and chlorambucil treatment in idiopathic membranous nephropathy with deteriorating renal function. Lancet 1988;2:869-72
   PubMed Web of Science ®Google Scholar
• Warwick GL, Geddes CG, Boulton-Jones JM. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure. Q J Med 1994;87:223-9
   PubMedGoogle Scholar
• Brunkhorst R, Wrenger E, Koch KM. Low-dose prednisolone/chlorambucil therapy in patients with severe membranous glomerulonephritis. Clin Invest 1994;72:277-80
   PubMedGoogle Scholar
• Reichert CJ, Koene KA, Wetzels JF, Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide. Ann Intern Med 1994;121:328-33
   PubMedGoogle Scholar
• Torres A, Dominguez-Gil B, Carreno A, Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 2002;61:219-27
   PubMed Web of Science ®Google Scholar
• Glassock RJ. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am J Kidney Dis 2004;44:562-6
   PubMedGoogle Scholar
• Passerini P, Como G, Vigano E, Idiopathic membranous nephropathy in the elderly. Nephrol Dial Transplant 1993;8:1321-5
   PubMed Web of Science ®Google Scholar
• Rollino C, Basolo B, Roccatello D, Outcome of membranous glomerulonephritis in the elderly. Contrib Nephrol 1993;105:71-4
   PubMedGoogle Scholar
• Deegens JK, Wetzels JF. Membranous nephropathy in the older adults: epidemiology, diagnosis and management. Drugs Aging 2007;24:717-32
   PubMed Web of Science ®Google Scholar
• Ponticelli C. Cyclosporine: from renal transplantation to autoimmune diseases. Ann NY Acad Sci 2005;1051:551-8
   PubMed Web of Science ®Google Scholar
• Iijima K, Hamahira K, Tanaka R, Risk factors for cyclosporine-induced tubulointerstitial lesions in children with minimal change nephrotic syndrome. Kidney Int 2002;61:1801-5
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Mosconi L, Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int 1998;53:1209-16
   PubMed Web of Science ®Google Scholar
• Fervenza FC. Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer? Clin J Am Soc Nephrol 2009;4:1017-9
   PubMedGoogle Scholar